Use of Eylea for the Treatment of an Optic Nerve Hemangioma
Part of paid clinical trials in New York, New York.
- Sponsor
- Vitreous -Retina- Macula Consultants of New York
- Study ID
- NCT01714115
- Status
- No Longer Available
Conditions
- Retinal Hemangioma
Eligibility Criteria
- Sex
- MALE
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Aflibercept — DRUG2.0 mg Intravitreal Injection, every 2 to 4 weeks
Study Details
This is a single patient investigative treatment study. The patient was diagnosed with a retinal tumor in one eye. In the last 2 years, the patient has been treated with all available and conventional therapies, including intraocular injections of Avastin and Lucentis, steroids, and photodynamic therapy. Any positive results were short-term, and caused an eventual decline in central vision. Aflibercept has been shown to be effective against the growth of new vessels, secondary to macular degeneration. This study proposes that it may also be more effective in treating this particular patient and case. The study treatment plan is for 6 months initially, with the intention to continue treatment.
Key Dates
- Status verified
- Aug 2017
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Vitreous Retina Macula Consultants of New York | New York | New York | 10022 | - |